background_placeholder
Monthly Prescribing Reference (MPR): Drugs in the Pipeline

Articles about Monthly Prescribing Reference (MPR): Drugs in the Pipeline

     
Kies meer

Trending
Er zijn @count nieuwe artikelen
Saturday, May 21, 2022 - 01:08 - In Wetenschap
NDA Submitted for Continuous SC Infusion Therapy for Parkinson Disease
Saturday, May 14, 2022 - 01:08 - In Trending
FDA Decision on Bimekizumab for Plaque Psoriasis Delayed
Friday, May 13, 2022 - 01:08 - In Trending
Efficacy Response Maintained With Deucravacitinib in Plaque Psoriasis Trial
Wednesday, May 11, 2022 - 22:40 - In Wetenschap
Upadacitinib Meets Endpoints in Crohn Disease Maintenance Trial
Monday, April 4, 2022 - 23:40 - In Trending
Dupilumab Gets Priority Review for Eosinophilic Esophagitis
Tuesday, March 15, 2022 - 19:32 - In Trending
FDA Extends Review Period for Ruxolitinib Cream for Vitiligo
Thursday, March 3, 2022 - 22:24 - In Trending
February 2022 Recap: Drug Pipeline Updates
Monday, February 28, 2022 - 21:32 - In Trending
FDA to Review Abrilada for Interchangeability With Humira
Tuesday, February 22, 2022 - 22:40 - In Trending
Trial Evaluating Dupilumab in Difficult-to-Treat Chronic Spontaneous Urticaria Stopped
Saturday, January 29, 2022 - 02:48 - In Trending
Lilly Ends Baricitinib Lupus Program, Provides Update on Atopic Dermatitis sNDA

Kies uw tags

e
dermatitis
eczema
psoriasis
erythema
urticaria
acne
melanoma
skin cancer
basal cell carcinoma
cellulitis
vitiligo
alopecia areata
hyperhidrosis